Oriola Corporation Stock Exchange Release
Q4 2021: Turnaround progressing - profitability continued to improve
October-
- Invoicing increased by 7.6% to
EUR 1,062.0 (986.6) million. On a constant currency basis invoicing increased by 6.5% and wasEUR 1,050.9 million . -
Net sales increased by 7.0% to
EUR 499.0 (466.2) million. On a constant currency basis net sales increased by 5.9% and wereEUR 493.7 million . -
Adjusted EBIT was
EUR 11.6 (8.0) million. On a constant currency basis the adjusted EBIT wasEUR 11.7 million . -
Profit for the period totalled
EUR 5.3 (4.1) million and earnings per share wereEUR 0.03 (0.02).
January-
- Invoicing increased by 5.2% to
EUR 3,959.1 (3,764.9) million. On a constant currency basis invoicing increased by 2.7% and wasEUR 3,868.3 million . -
Net sales increased by 4.5% to
EUR 1,882.4 (1,800.8) million. On a constant currency basis net sales increased by 1.9% and wereEUR 1,835.9 million . -
Adjusted EBIT was
EUR 26.3 (21.0) million. On a constant currency basis the adjusted EBIT wasEUR 25.6 million . -
Profit for the period totalled
EUR 11.3 (11.3) million and earnings per share wereEUR 0.06 (0.06). -
The Board of Directors proposes to the Annual General Meeting that a dividend of
EUR 0.04 (0.03) per share would be paid for 2021.
Key figures | 2021 | 2020 | Change | 2021 | 2020 | Change |
EUR million | 10-12 | 10-12 | % | 1-12 | 1-12 | % |
Invoicing | 1,062.0 | 986.6 | 7.6 | 3,959.1 | 3,764.9 | 5.2 |
Net sales | 499.0 | 466.2 | 7.0 | 1,882.4 | 1,800.8 | 4.5 |
Adjusted EBIT1 | 11.6 | 8.0 | 45.1 | 26.3 | 21.0 | 25.5 |
EBIT | 8.1 | 6.8 | 18.7 | 20.5 | 20.4 | 0.5 |
Adjusted EBIT % | 2.3 | 1.7 |
| 1.4 | 1.2 |
|
EBIT % | 1.6 | 1.5 |
| 1.1 | 1.1 |
|
Profit for the period | 5.3 | 4.1 | 29.5 | 11.3 | 11.3 | 0.5 |
Earnings per share, EUR | 0.03 | 0.02 | 29.5 | 0.06 | 0.06 | 0.5 |
Net cash flow from operating activities | 42.2 | 45.7 |
| 40.0 | 58.3 |
|
|
|
|
|
|
|
|
Gearing, % |
|
|
| 46.5 | 75.0 |
|
Equity ratio, % |
|
|
| 20.1 | 14.8 |
|
Return on capital employed (ROCE), % |
|
|
| 4.6 | 5.0 |
|
1 Adjusting items are specified in note 12. Adjusting items.
|
In order to reflect the underlying business performance and to enhance comparability between financial periods
Outlook for 2022
The adjusted EBIT is estimated to increase from the 2021 level.
The COVID-19 pandemic continues and severity as well as duration of the pandemic remain unclear in
The outlook is based on current group structure.
CEO
"For
In the fourth quarter the adjusted EBIT increased to
During the second half of the year
Year 2021 ended with the new pandemic wave challenging again our operations due to the increased absence rates of our personnel. As a critical supplier of the pharmaceuticals, we have done our utmost to secure deliveries to the pharmacies and hospitals as well as to the Swedish consumers through our pharmacies. I want to thank all our employees for taking the extra mile as well as customers and business partners for the good cooperation during these extraordinary times."
Disclosure procedure
This
Analyst and investor meeting
Publication of the Financial Statements
Further information:
CEO
Tel. +358 10 429 2109
Email: elisa.markula@oriola.com
CFO
Email: sari.pohjonen@oriola.com
Distribution:
Key media
Released by:
Corporate Communications
Orionintie 5
FI-02200 Espoo
www.oriola.com
https://news.cision.com/oriola-oyj/r/oriola-corporation-s-financial-statements-release-1-january---31-december-2021,c3509615
https://mb.cision.com/Main/15459/3509615/1537190.pdf
(c) 2022 Cision. All rights reserved., source